NASDAQ:ARWRArrowhead Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $35.16 -1.56 (-4.25 %) (As of 05/26/2020 12:54 PM ET) Add Compare Share Today's Range$35.00Now: $35.16▼$36.8850-Day Range$26.12MA: $35.03▼$39.4752-Week Range$19.51Now: $35.16▼$73.72Volume38,444 shsAverage Volume1.14 million shsMarket Capitalization$3.58 billionP/E Ratio390.71Dividend YieldN/ABeta1.82 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $62.00, Arrowhead Pharmaceuticals has a potential upside of 76.3% from its current price of $35.16.Amount of Analyst CoverageArrowhead Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesArrowhead Pharmaceuticals has received 466 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArrowhead Pharmaceuticals has received 454 “underperform” votes. (Add your “underperform” vote.)Community SentimentArrowhead Pharmaceuticals has received 50.65% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote “Outperform” if you believe ARWR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,164,730.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions64.26% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($0.54) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is 390.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 13.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is 390.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.19.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 13.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.58 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARWR Previous Symbol CUSIPN/A CIK879407 Webwww.arrowheadpharma.com Phone626-304-3400Debt Debt-to-Equity Ratio0.03 Current Ratio5.90 Quick Ratio5.90Price-To-Earnings Trailing P/E Ratio390.71 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$168.80 million Price / Sales21.20 Cash Flow$0.76 per share Price / Cash Flow46.05 Book Value$2.57 per share Price / Book13.68Profitability EPS (Most Recent Fiscal Year)$0.69 Net Income$67.97 million Net Margins6.86% Return on Equity2.61% Return on Assets2.08%Miscellaneous Employees116 Outstanding Shares101,770,000Market Cap$3.58 billion Next Earnings Date8/3/2020 (Estimated) OptionableOptionable NASDAQ:ARWR Rates by TradingView Receive ARWR News and Ratings via Email Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions How has Arrowhead Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARWR stock has increased by 23.1% and is now trading at $35.16. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Arrowhead Pharmaceuticals? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arrowhead Pharmaceuticals. When is Arrowhead Pharmaceuticals' next earnings date? Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Arrowhead Pharmaceuticals. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) posted its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.09. The biotechnology company earned $23.53 million during the quarter, compared to analyst estimates of $21.90 million. Arrowhead Pharmaceuticals had a net margin of 6.86% and a return on equity of 2.61%. View Arrowhead Pharmaceuticals' earnings history. What price target have analysts set for ARWR? 10 brokers have issued 1 year price targets for Arrowhead Pharmaceuticals' stock. Their forecasts range from $29.00 to $81.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $62.00 in the next year. This suggests a possible upside of 76.3% from the stock's current price. View analysts' price targets for Arrowhead Pharmaceuticals. Has Arrowhead Pharmaceuticals been receiving favorable news coverage? Headlines about ARWR stock have trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Arrowhead Pharmaceuticals earned a daily sentiment score of -5.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutArrowhead Pharmaceuticals. Who are some of Arrowhead Pharmaceuticals' key competitors? Some companies that are related to Arrowhead Pharmaceuticals include Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Catalent (CTLT), Sarepta Therapeutics (SRPT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Mylan (MYL), Ionis Pharmaceuticals (IONS), Perrigo (PRGO) and Elanco Animal Health (ELAN). View all competitors. What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Micron Technology (MU), Bank of America (BAC), Alliance Resource Partners (ARLP), Sasol (SSL), Sarepta Therapeutics (SRPT) and Advanced Micro Devices (AMD). Who are Arrowhead Pharmaceuticals' key executives? Arrowhead Pharmaceuticals' management team includes the following people: Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 50)Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 53)Dr. Bruce D. Given, Chief Operating Officer (Age 65)Mr. Patrick O'Brien, Gen. Counsel (Age 55)Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando What is Arrowhead Pharmaceuticals' stock symbol? Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR." Who are Arrowhead Pharmaceuticals' major shareholders? Arrowhead Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.23%), State Street Corp (4.22%), Invesco Ltd. (3.11%), First Manhattan Co. (1.59%), Geode Capital Management LLC (1.49%) and Fiera Capital Corp (1.31%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View institutional ownership trends for Arrowhead Pharmaceuticals. Which major investors are selling Arrowhead Pharmaceuticals stock? ARWR stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Deutsche Bank AG, UBS Group AG, JPMorgan Chase & Co., Principal Financial Group Inc., Invesco Ltd., First Trust Advisors LP, and Federated Hermes Inc.. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, and Patrick O'brien. View insider buying and selling activity for Arrowhead Pharmaceuticals. Which major investors are buying Arrowhead Pharmaceuticals stock? ARWR stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Nuveen Asset Management LLC, AQR Capital Management LLC, State Street Corp, Prosight Management LP, and Quantitative Investment Management LLC. View insider buying and selling activity for Arrowhead Pharmaceuticals. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Arrowhead Pharmaceuticals' stock price today? One share of ARWR stock can currently be purchased for approximately $35.16. How big of a company is Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals has a market capitalization of $3.58 billion and generates $168.80 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or $0.69 on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe. What is Arrowhead Pharmaceuticals' official website? The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com. How can I contact Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected] This page was last updated on 5/26/2020 by MarketBeat.com Staff
